National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, ACT
National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, ACT.
Med J Aust. 2018 Jun 2;209(1):35-41. doi: 10.5694/mja17.00897. Epub 2018 Jun 25.
To quantify absolute cardiovascular disease (CVD) risk in Aboriginal and Torres Strait Islander people and their use of lipid-lowering therapies.
DESIGN, PARTICIPANTS: Cross-sectional analysis of nationally representative data from 2820 participants aged 18-74 years who provided biomedical data for the National Aboriginal and Torres Strait Islander Health Measures Survey component of the 2012-13 Australian Aboriginal and Torres Strait Islander Health Survey.
Prior CVD and use of lipid-lowering medications were ascertained at interview. 5-year absolute risk of a primary CVD event was calculated with the Australian National Vascular Disease Prevention Alliance algorithm, with categories low (< 10%), moderate (10-15%) and high risk (> 15%).
Among participants aged 35-74 years, 9.6% (95% CI, 7.2-12.0%) had prior CVD; 15.7% (95% CI, 13.0-18.3%) were at high, 4.9% (95% CI, 3.3-6.6%) at moderate, and 69.8% (95% CI, 66.8-72.8%) at low absolute primary CVD risk. 82.6% of those at high primary risk were identified on the basis of clinical criteria. High primary absolute risk affected 1.1% (95% CI, 0.0-2.5%) of 18-24-year-olds, 4.7% (95% CI, 2.0-7.5%) of 25-34-year-olds, and 44.2% (95% CI, 33.1-55.3%) of 65-74-year-olds. Lipid-lowering therapy was being used by 52.9% (95% CI, 38.2-67.6%) of people aged 35-74 years with prior CVD and by 42.2% (95% CI, 30.5-53.8%) of those at high primary CVD risk.
Absolute CVD risk is high among Aboriginal and Torres Strait Islander people, and most of those at high risk are undertreated. Substantial proportions of people under 35 years of age are at high risk, but are not targeted by current guidelines for absolute CVD risk assessment, compromising CVD prevention in this population.
量化原住民和托雷斯海峡岛民的绝对心血管疾病(CVD)风险,并评估他们使用降脂药物的情况。
设计、参与者:对参加 2012-13 年澳大利亚原住民和托雷斯海峡岛民健康调查的 2820 名 18-74 岁参与者的全国代表性数据进行横断面分析,这些参与者提供了生物医学数据。
通过访谈确定既往 CVD 病史和降脂药物的使用情况。使用澳大利亚国家血管疾病预防联盟算法计算主要 CVD 事件的 5 年绝对风险,风险类别为低(<10%)、中(10-15%)和高(>15%)。
在 35-74 岁的参与者中,9.6%(95%CI,7.2-12.0%)有既往 CVD;15.7%(95%CI,13.0-18.3%)处于高风险,4.9%(95%CI,3.3-6.6%)处于中风险,69.8%(95%CI,66.8-72.8%)处于低绝对主要 CVD 风险。基于临床标准,82.6%的高风险人群被识别。高绝对风险影响 1.1%(95%CI,0.0-2.5%)的 18-24 岁人群,4.7%(95%CI,2.0-7.5%)的 25-34 岁人群和 44.2%(95%CI,33.1-55.3%)的 65-74 岁人群。既往 CVD 患者中有 52.9%(95%CI,38.2-67.6%)和高 CVD 风险患者中有 42.2%(95%CI,30.5-53.8%)使用降脂药物。
原住民和托雷斯海峡岛民的绝对 CVD 风险较高,大多数高风险人群治疗不足。相当一部分 35 岁以下人群处于高风险,但目前的绝对 CVD 风险评估指南并未针对这部分人群,这影响了该人群的 CVD 预防。